Filtered By:
Condition: Anemia
Drug: Taxotere
This page shows you your search results in order of date.
Order by Relevance | Date
Total 45 results found since Jan 2013.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial
This study is registered with ClinicalTrials.gov, NCT03732820, and is completed and no longer recruiting.FINDINGS: Between Oct 31, 2018 and March 11, 2020, 1103 patients were screened, of whom 399 were randomly assigned to olaparib plus abiraterone and 397 to placebo plus abiraterone. Median follow-up for overall survival in patients with censored data was 36·6 months (IQR 34·1-40·3) for olaparib plus abiraterone and 36·5 months (33·8-40·3) for placebo plus abiraterone. Median overall survival was 42·1 months (95% CI 38·4-not reached) with olaparib plus abiraterone and 34·7 months (31·0-39·3) with placebo plus a...
Source: Cancer Control - September 15, 2023 Category: Cancer & Oncology Authors: Fred Saad Noel W Clarke Mototsugu Oya Neal Shore Giuseppe Procopio Jo ão Daniel Guedes Cagatay Arslan Niven Mehra Francis Parnis Emma Brown Friederike Schl ürmann Jae Young Joung Mikio Sugimoto Oliver Sartor Yu-Zhen Liu Christian Poehlein Laura Barker P Source Type: research
EV-301 long-term outcomes: 24-month findings from the phase III trial of enfortumab vedotin vs chemotherapy in patients with previously treated advanced urothelial carcinoma
CONCLUSIONS: After median follow-up of approximately 2 years, enfortumab vedotin maintained clinically meaningful overall survival benefit versus chemotherapy, consistent with findings from the EV-301 primary analysis; PFS and overall response benefit remained consistent. Adverse events were manageable; no new safety signals were observed.PMID:37678672 | DOI:10.1016/j.annonc.2023.08.016
Source: Ann Oncol - September 7, 2023 Category: Cancer & Oncology Authors: J E Rosenberg T Powles G P Sonpavde Y Loriot I Duran J-L Lee N Matsubara C Vulsteke D Castellano R Mamtani C Wu M Matsangou M Campbell D P Petrylak Source Type: research
Phase II study of docetaxel and trametinib in patients with KRAS mutation positive recurrent non-small cell lung cancer (NSCLC) (SWOG S1507, NCT-02642042)
CONCLUSIONS: RRs were significantly improved in the overall population. Contrary to pre-clinical studies, the combination showed no improvement in efficacy in G12C patients. Co-mutations may influence therapeutic efficacy of KRAS directed therapies and are worthy of further evaluation.PMID:37233987 | DOI:10.1158/1078-0432.CCR-22-3947
Source: Clinical Lung Cancer - May 26, 2023 Category: Cancer & Oncology Authors: Shirish M Gadgeel Jieling Miao Jonathan W Riess James Moon Philip C Mack Gregory J Gerstner Timothy F Burns Asma Taj Wallace L Akerley Konstantin H Dragnev Noel Laudi Mary W Redman Jhanelle E Gray David R Gandara Karen Kelly Source Type: research
Efficacy and Safety of Platinum-based Chemotherapy With Bevacizumab Followed by Bevacizumab Maintenance for Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer During PARP Inhibitor Therapy: A Multicenter Retrospective Study
CONCLUSION: Platinum-based chemotherapy with BEV followed by BEV maintenance for platinum-sensitive recurrence during PARP inhibitor treatment was shown to be efficacious and safe. This combination should be further evaluated in larger randomized clinical trials.PMID:36854492 | DOI:10.21873/anticanres.16273
Source: Cancer Control - February 28, 2023 Category: Cancer & Oncology Authors: Marina Abe Tadahiro Shoji Yohei Chiba Eriko Takatori Yoshitaka Kaido Takayuki Nagasawa Masahiro Kagabu Fumiaki Takahashi Takeshi Aida Tsukasa Baba Source Type: research
Phase I study of LZM005 in patients with HER2-positive metastatic breast cancer
NPJ Breast Cancer. 2022 Dec 27;8(1):132. doi: 10.1038/s41523-022-00501-2.ABSTRACTThe prognosis of human epidermal growth factor receptor 2 (HER2) positive metastatic breast cancer (MBC) remained unsatisfactory currently, more anti-HER2 agents are needed. Here we report a phase I study that evaluated the safety, activity, and biomarkers of LZM005, a HER2 antibody, used as a monotherapy or in combination with trastuzumab plus docetaxel in patients with HER2-positive MBC. From October 2017 to December 2019, 34 patients received LZM005 (14 monotherapy, 20 combination therapy). No DLT was observed. The common adverse events (AE...
Source: Cancer Control - December 27, 2022 Category: Cancer & Oncology Authors: Cong Xue Haifeng Li Herui Yao Ying Lin Xin An Meiting Chen Riqing Huang Lu Li Anqi Hu Mengqian Ni Lulu Zhang Wei Yang Zhonghui Xu Su Li Yanxia Shi Source Type: research
A prospective, open-label, multicenter phase IV clinical trial on the safety and efficacy of lobaplatin-based chemotherapy in advanced breast cancer
CONCLUSION: LBP-based chemotherapy shows favorable efficacy in patients with advanced breast cancer, with manageable safety profile.TRIAL REGISTRATION: This trial was registered with ChiCTR.org.cn, ChiCTR-ONC-13003471.PMID:36330235 | PMC:PMC9623367 | DOI:10.1177/17588359221122715
Source: Cancer Control - November 4, 2022 Category: Cancer & Oncology Authors: Min Yan Peng Yuan Quchang Ouyang Ying Cheng Guohui Han Dewei Wang Li Ran Tao Sun Da Zhao Yuju Bai Shun'e Yang Xiaojia Wang Rong Wu Xiaohua Zeng Herui Yao Xuening Ji Jun Jiang Xiaohua Hu Haifeng Lin Liping Zheng Zhitu Zhu Wei Ge Junlan Yang Tongjian Cui Xi Source Type: research
Clinical Application of Anlotinib Combined with Docetaxel: Safe and Effective Treatment for Lung Carcinoma
CONCLUSION: Anlotinib combined with docetaxel is a safe and effective treatment for lung carcinoma to reduce the incidence of adverse reactions and improve the long-term survival rate. These benefits make it worthy of a broader clinical application. Although pharmacological treatment was applied in this study based on the mechanism, specific bioeffective markers are yet to be identified, presenting a direction for future research.PMID:36277984 | PMC:PMC9586802 | DOI:10.1155/2022/2483816
Source: Cancer Control - October 24, 2022 Category: Cancer & Oncology Authors: Xiang Ji Xin Jing Yongshi Liu Jiangbo Huang Sanhu Yang Yuhui Yun Source Type: research
Polymorphisms in solute carrier genes (SLC19A1, SLCO1B1, and SLCO1B3) predicts survival and toxicity in North Indian lung cancer patients undergoing platinum-based doublet chemotherapy
CONCLUSION: Our findings imply that Solute Carrier gene polymorphisms modulate the overall survival in lung cancer patients undergoing platin-based doublet chemotherapy, also these polymorphisms have a modifying impact on the associated adverse events/toxicity.PMID:35896189 | DOI:10.1111/jcpt.13748
Source: Clinical Lung Cancer - July 27, 2022 Category: Cancer & Oncology Authors: Parul Sharma Navneet Singh Siddharth Sharma Source Type: research
